Detalles de la búsqueda
1.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Ann Oncol
; 33(2): 181-192, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34839016
2.
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Ann Oncol
; 31(8): 1056-1064, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32418886
3.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Ann Oncol
; 30(8): 1321-1328, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125062
4.
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Ann Oncol
; 29(11): 2214-2222, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30215676
5.
Cross-cultural adaptation and validation of the Spanish version of the Paediatric Throat Disorders Outcome Test (T-14).
Clin Otolaryngol
; 43(2): 598-603, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29119714
6.
Classification of atypical EGFR mutations in non-small-cell lung cancer.
Ann Oncol
; 33(6): 571-573, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35331813
7.
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.
Ann Oncol
; 28(9): 2248-2255, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28911086
8.
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Ann Oncol
; 27(2): 281-6, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26598547
9.
DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
Tumour Biol
; 37(10): 13435-13443, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27465548
10.
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ann Oncol
; 26(8): 1741-8, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25997818
11.
A randomised double blind clinical trial to compare surgical field bleeding during endoscopic sinus surgery with clonidine-based or remifentanil-based hypotensive anaesthesia.
Rhinology
; 53(2): 107-15, 2015 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26030032
12.
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Br J Cancer
; 110(11): 2662-8, 2014 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24809779
13.
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Ann Oncol
; 25(11): 2147-2155, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25164908
14.
Hypotensive anaesthesia and bleeding during endoscopic sinus surgery: an observational study.
Eur Arch Otorhinolaryngol
; 271(6): 1505-11, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24052249
15.
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
ESMO Open
; 9(2): 102237, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38350336
16.
Combining plasma-based biosources to predict treatment response in NSCLC patients.
Ann Oncol
; 29(9): 2022, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010765
17.
Combining plasma-based biosources to predict treatment response in NSCLC patients.
Ann Oncol
; 29(9): 2018, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32138978
18.
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Ann Oncol
; 23(1): 86-93, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21471564
19.
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
Eur Respir J
; 39(2): 366-72, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21778168
20.
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
Lung Cancer
; 164: 8-13, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34971901